Update! Watching
$Biotricity (BTCY.US)$ Biotricity Provides Year-End Guidance With Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
Accesswire·
Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is excited to provide guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets.
Revenue Growth is expected to exceed 24% YoY
Loss from Operations is expected to decrease by over 40% YoY
Margins are expected to improve by over 10% YoY
"These developments are key indicators of the company's continued execution and upcoming milestone of achieving cashflow breakeven," remarked Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "We have shown continued YoY growth while improving losses and margins. This combination of growth, reduction in losses and margin improvement are a path to profitability. Biotricity is among the few who experience all three simultaneously.
These developments are a result of Biotricity's continued excellence in the market and its business model, driving higher adoption of its solutions and increasing revenues. The company's TaaS model is characterized by excellent margins and customer retention with improving operational efficiency, making it a leader within the cardiac market.
Accesswire·
Company expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ:BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is excited to provide guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets.
Revenue Growth is expected to exceed 24% YoY
Loss from Operations is expected to decrease by over 40% YoY
Margins are expected to improve by over 10% YoY
"These developments are key indicators of the company's continued execution and upcoming milestone of achieving cashflow breakeven," remarked Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "We have shown continued YoY growth while improving losses and margins. This combination of growth, reduction in losses and margin improvement are a path to profitability. Biotricity is among the few who experience all three simultaneously.
These developments are a result of Biotricity's continued excellence in the market and its business model, driving higher adoption of its solutions and increasing revenues. The company's TaaS model is characterized by excellent margins and customer retention with improving operational efficiency, making it a leader within the cardiac market.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
